Trial Supports Wider Use of Vernalis and Endo's Migraine Drug
Posted on: Monday, 8 May 2006, 12:02 CDT
Vernalis and Endo Pharmaceuticals' migraine medication Frova has achieved positive results in a phase III study designed to evaluate the drug in an additional indication of menstrual migraine.
Endo expects to file a supplemental new drug application with the FDA in the coming weeks to seek approval for the expanded indication. Frova is currently approved for the acute treatment of migraine attacks with or without aura in adults where a clear diagnosis of migraine has been established.
Both once and twice-daily dose regimens of Frova demonstrated efficacy, achieving a statistically significant improvement over placebo in the trials primary endpoint of the number of menstrual migraine-free peri-menstrual periods.
"We are delighted to have achieved a positive outcome from this confirmatory efficacy trial with Frova. The women in this study represent a difficult-to-treat population, each having previously failed acute therapy. These results underscore our belief in the potential of Frova," said Simon Sturge, CEO of Vernalis.
Source: Datamonitor
Related Articles
- Vernalis and Paul Capital Healthcare Sign Euro 18.4 Million Financing Agreement
- Endo Pharmaceuticals and Vernalis Receive Action Letter From FDA on FROVA(R) Supplemental New Drug Application
- FROVA (R) Phase III Study Data Demonstrates That Short-Term Prevention Treatment Reduces Frequency and Severity of Menstrual Migraine
- Vernalis Plc Initiates a Phase I Trial of a Promising New Approach to Treating Obesity and Related Disorders - Including Type II Diabetes
- Vernalis Plc Announces FDA Acceptance for Filing of Frova(R) for Short-Term Prevention of Menstrual Migraine
- Vernalis Plc: Interim Results for the Six Months Ended 30 June 2006
- Endo Seeks Approval for Frova in Menstrual Migraine
- Endo Pharmaceuticals and Vernalis Plc Announce the Filing of the Supplemental NDA for Frova(R) for Short-Term Prevention of Menstrual Migraine
- Frova(R) Meets Primary Endpoint in Second Phase III Study for Prevention of Menstrual Migraine
- Serena Williams Launches 'RALLY for Menstrual Migraine' Campaign With Endo Pharmaceuticals
 |
 |
User Comments (0)
RSS Feeds